192 related articles for article (PubMed ID: 15267249)
1. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation.
Moyle PM; Olive C; Ho MF; Good MF; Toth I
J Med Chem; 2006 Oct; 49(21):6364-70. PubMed ID: 17034142
[TBL] [Abstract][Full Text] [Related]
3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
5. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
7. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I
J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857
[TBL] [Abstract][Full Text] [Related]
8. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
9. Method for the synthesis of highly pure vaccines using the lipid core peptide system.
Moyle PM; Olive C; Good MF; Toth I
J Pept Sci; 2006 Dec; 12(12):800-7. PubMed ID: 17131293
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
12. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
Bessen D; Fischetti VA
J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology.
Hayman WA; Toth I; Flinn N; Scanlon M; Good MF
Immunol Cell Biol; 2002 Apr; 80(2):178-87. PubMed ID: 11940119
[TBL] [Abstract][Full Text] [Related]
14. Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation.
Moyle PM; Olive C; Ho MF; Burgess M; Karpati L; Good MF; Toth I
J Org Chem; 2006 Sep; 71(18):6846-50. PubMed ID: 16930036
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
16. Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non-opsonic epitopes.
Sandin C; Carlsson F; Lindahl G
Mol Microbiol; 2006 Jan; 59(1):20-30. PubMed ID: 16359315
[TBL] [Abstract][Full Text] [Related]
17. Mapping a conserved conformational epitope from the M protein of group A streptococci.
Relf WA; Cooper J; Brandt ER; Hayman WA; Anders RF; Pruksakorn S; Currie B; Saul A; Good MF
Pept Res; 1996; 9(1):12-20. PubMed ID: 8727479
[TBL] [Abstract][Full Text] [Related]
18. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
19. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
Bronze MS; Courtney HS; Dale JB
J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
[TBL] [Abstract][Full Text] [Related]
20. Development of conformational mimetics of conserved Streptococcus pyogenes minimal epitope as vaccine candidates.
Zhong W; Skwarczynski M; Toth I
Curr Drug Deliv; 2009 Oct; 6(5):520-7. PubMed ID: 19863488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]